ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1089

Large Variations in Tuberculosis Testing for New Biologic Users with Rheumatoid Arthritis Among Providers in the RISE Registry

Gabriela Schmajuk1, Michael Evans2, Julia Kay3 and Jinoos Yazdany4, 1San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, 2University of California San Francisco, San Francisco, CA, 3Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, 4Medicine/Rheumatology, University of California San Francisco, San Francisco, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: registries, rheumatoid arthritis (RA) and tuberculosis, Safety issues

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Measures and Measurement of Healthcare Quality Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Tuberculosis (TB) testing prior to biologic DMARD use helps prevent potentially fatal, medication-related adverse events and is a National Quality Forum-endorsed quality measure. We used data from a national registry to describe practice variations on this measure among US rheumatologists.

Methods: The ACR’s RISE is a national registry that passively collects electronic health record (EHR) data on all patients seen by participating practices.  As of December 2016, RISE was connected to 632 providers representing an estimated 20% of the US clinical rheumatology workforce.  We calculated the proportion patients ≥ 18 with rheumatoid arthritis who were newly prescribed a biologic DMARD or tofacitinib during 2016 and who had TB testing in the 12 months preceding the biologic prescription, by practice and geographic region. We examined associated EHR data for the type of TB test performed (PPD or quantiferon-based assays). Consistent with other national performance analyses, providers with fewer than 30 qualifying patients in the denominator were excluded.  Proportions were compared using chi-square tests.

Results: We analyzed data from 18,079 patients across 533 providers and 95 practices. 77% of patients were female, 20% were non-white, and mean age was 58 (SD 13.5). Overall, patient-level performance on the measure was 56%, with a range of 0 to 96% across practices (Figure), and significant variation across regions (Table; p<0.0001). Among the patients in the numerator with a TB test found in the EHR data (N=7828), 93% received a Quantiferon test while 7% had a PPD.

Conclusion: We found large variations in TB testing prior to new biologic DMARD starts across RISE practices.  Given that quantiferon-based assays represented the majority of TB screening tests identified, we suspect that PPD testing remains undercaptured in the EHR. As value-based incentive programs become more widespread, accurate capture of performance on patient safety measures will be increasingly important and may require practices to standardize documentation of important safety processes such as TB testing.

Disclaimer: The data presented here was supported by the ACR’s RISE Registry. However, the views expressed represent those of the authors and do not necessarily represent the views of the ACR.


Disclosure: G. Schmajuk, None; M. Evans, None; J. Kay, None; J. Yazdany, None.

To cite this abstract in AMA style:

Schmajuk G, Evans M, Kay J, Yazdany J. Large Variations in Tuberculosis Testing for New Biologic Users with Rheumatoid Arthritis Among Providers in the RISE Registry [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/large-variations-in-tuberculosis-testing-for-new-biologic-users-with-rheumatoid-arthritis-among-providers-in-the-rise-registry/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/large-variations-in-tuberculosis-testing-for-new-biologic-users-with-rheumatoid-arthritis-among-providers-in-the-rise-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences